BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 21204713)

  • 21. New molecular assays for cancer diagnosis and targeted therapy.
    Lea P; Ling M
    Curr Opin Mol Ther; 2008 Jun; 10(3):251-9. PubMed ID: 18535932
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular cytogenetics in solid tumors: laboratorial tool for diagnosis, prognosis, and therapy.
    Varella-Garcia M
    Oncologist; 2003; 8(1):45-58. PubMed ID: 12604731
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Morphological control for molecular testing: a practical approach.
    Gullo I; Marques A; Pinto R; Cirnes L; Schmitt F
    J Clin Pathol; 2021 May; 74(5):331-333. PubMed ID: 32763918
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
    Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
    Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular testing in solid tumors: an overview.
    Hunt JL
    Arch Pathol Lab Med; 2008 Feb; 132(2):164-7. PubMed ID: 18251569
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Molecular Pathology Diagnosis as Companion Diagnostics].
    Fujii S
    Gan To Kagaku Ryoho; 2024 Apr; 51(4):383-387. PubMed ID: 38644301
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Integrating Molecular Testing in the Diagnosis and Management of Children with Thyroid Lesions.
    Ballester LY; Sarabia SF; Sayeed H; Patel N; Baalwa J; Athanassaki I; Hernandez JA; Fang E; Quintanilla NM; Roy A; López-Terrada DH
    Pediatr Dev Pathol; 2016; 19(2):94-100. PubMed ID: 26366474
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular Testing and the Pathologist's Role in Clinical Trials of Breast Cancer.
    Han HS; Magliocco AM
    Clin Breast Cancer; 2016 Jun; 16(3):166-79. PubMed ID: 27103546
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.
    Beltran H; Eng K; Mosquera JM; Sigaras A; Romanel A; Rennert H; Kossai M; Pauli C; Faltas B; Fontugne J; Park K; Banfelder J; Prandi D; Madhukar N; Zhang T; Padilla J; Greco N; McNary TJ; Herrscher E; Wilkes D; MacDonald TY; Xue H; Vacic V; Emde AK; Oschwald D; Tan AY; Chen Z; Collins C; Gleave ME; Wang Y; Chakravarty D; Schiffman M; Kim R; Campagne F; Robinson BD; Nanus DM; Tagawa ST; Xiang JZ; Smogorzewska A; Demichelis F; Rickman DS; Sboner A; Elemento O; Rubin MA
    JAMA Oncol; 2015 Jul; 1(4):466-74. PubMed ID: 26181256
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PSF/SFPQ is a very common gene fusion partner in TFE3 rearrangement-associated perivascular epithelioid cell tumors (PEComas) and melanotic Xp11 translocation renal cancers: clinicopathologic, immunohistochemical, and molecular characteristics suggesting classification as a distinct entity.
    Rao Q; Shen Q; Xia QY; Wang ZY; Liu B; Shi SS; Shi QL; Yin HL; Wu B; Ye SB; Li L; Chen JY; Pan MH; Li Q; Li R; Wang X; Zhang RS; Yu B; Ma HH; Lu ZF; Zhou XJ
    Am J Surg Pathol; 2015 Sep; 39(9):1181-96. PubMed ID: 26274027
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cancer diagnostics: The journey from histomorphology to molecular profiling.
    Ahmed AA; Abedalthagafi M
    Oncotarget; 2016 Sep; 7(36):58696-58708. PubMed ID: 27509178
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The evolving clinical testing landscape of genomic aberrations in solid tumors and hematological malignancies - Insights from evidence-based reviews for B-ALL and breast, brain, and renal cell neoplasia.
    Miron PM; Fang M
    Cancer Genet; 2020 Jun; 244():60-61. PubMed ID: 32473557
    [No Abstract]   [Full Text] [Related]  

  • 33. Clinical significance of cytogenetic findings in solid tumors.
    Mitelman F; Johansson B; Mandahl N; Mertens F
    Cancer Genet Cytogenet; 1997 May; 95(1):1-8. PubMed ID: 9140447
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Companion diagnostic testing for targeted cancer therapies: an overview.
    Fan YS
    Genet Test Mol Biomarkers; 2013 Jul; 17(7):515-23. PubMed ID: 23574530
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lung Carcinoma Predictive Biomarker Testing by Immunoperoxidase Stains in Cytology and Small Biopsy Specimens: Advantages and Limitations.
    Zhou F; Moreira AL
    Arch Pathol Lab Med; 2016 Dec; 140(12):1331-1337. PubMed ID: 27588333
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cancer Targeted Therapy Strategy: The Pathologist's Perspectives.
    Alessandrini L; Perin T; Kadare S; Del Pup L; Memeo L; Steffan A; Colarossi L; Berretta M; De Paoli P; Canzonieri V
    Curr Cancer Drug Targets; 2018; 18(5):410-420. PubMed ID: 29189158
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical Practice Guideline: Evaluation of the Neck Mass in Adults.
    Pynnonen MA; Gillespie MB; Roman B; Rosenfeld RM; Tunkel DE; Bontempo L; Brook I; Chick DA; Colandrea M; Finestone SA; Fowler JC; Griffith CC; Henson Z; Levine C; Mehta V; Salama A; Scharpf J; Shatzkes DR; Stern WB; Youngerman JS; Corrigan MD
    Otolaryngol Head Neck Surg; 2017 Sep; 157(2_suppl):S1-S30. PubMed ID: 28891406
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ETV6 gene aberrations in non-haematological malignancies: A review highlighting ETV6 associated fusion genes in solid tumors.
    Biswas A; Rajesh Y; Mitra P; Mandal M
    Biochim Biophys Acta Rev Cancer; 2020 Aug; 1874(1):188389. PubMed ID: 32659251
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mutation Yield of a 34-Gene Solid Tumor Panel in Community-Based Tumor Samples.
    Sanders H; Qu K; Li H; Ma L; Barlan C; Zhang X; Prentice J; Wolfson D; Crossley B; Sferruzza A; Sninsky J; Ross D; Grupe A; Catanese J; Hantash F; Waldman F
    Mol Diagn Ther; 2016 Jun; 20(3):241-53. PubMed ID: 27084556
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma.
    Cai G; Wong R; Chhieng D; Levy GH; Gettinger SN; Herbst RS; Puchalski JT; Homer RJ; Hui P
    Cancer Cytopathol; 2013 Sep; 121(9):500-7. PubMed ID: 23495083
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.